Talking about the scoping study and recovery rates.
The importance of high recovery rates using HPAL cannot be overstated. The NPV due to capital cost is going to be a bummer in my view but if analysts see the recovery rates affording healthy feed stock then we get a big tick as @roblun has suggested numerous times.
Also if the NPV and IRR are not great the analysts should factor in the the other 50% of Mt Thirsty that GAL has.
I don't put much weight on the scandium and it is not included in this study anyway so the capital cost should not factor in a scandium circuit.
Ann: Addendum to 2023 Notice of Annual General Meeting, page-7
Add to My Watchlist
What is My Watchlist?